bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2020.04.30.071100

Evidence for unique small RNA modifications in Alzheimers disease

Zhang, X.·Trebak, F.·Souza, L. A. C.·Shi, J.·Zhou, T.·Kehoe, P. G.·Chen, Q.·Feng Earley, Y.
View original source ↗Export metadata ↓

Abstract

BackgroundWhile significant advances have been made in uncovering the aetiology of Alzheimers disease and related dementias at the genetic level, molecular events at the epigenetic level remain largely undefined. Emerging evidence indicates that small non-coding RNAs (sncRNAs) and their associated RNA modifications are important regulators of complex physiological and pathological processes, including aging, stress responses, and epigenetic inheritance. However, whether small RNAs and their modifications are altered in dementia is not known. MethodsWe performed LC-MS/MS-based, high-throughput assays of small RNA modifications in post-mortem samples of the prefrontal lobe cortices of Alzheimers disease (AD) and control individuals. We noted that some of the AD patients has co-occurring vascular cognitive impairment-related pathology (VaD). FindingsWe report altered small RNA modifications in AD samples compared with normal controls. The 15-25-nucleotide (nt) RNA fraction of these samples was enriched for microRNAs, whereas the 30-40-nt RNA fraction was enriched for tRNA-derived small RNAs (tsRNAs), rRNA-derived small RNAs (rsRNAs), and YRNA-derived small RNAs (ysRNAs). Interestingly, most of these altered RNA modifications were detected both in the AD and AD with co-occurring vascular dementia subjects. In addition, sequencing of small RNA in the 30-40-nt fraction from AD cortices revealed reductions in rsRNA-5S, tsRNA-Tyr, and tsRNA-Arg. InterpretationThese data suggest that sncRNAs and their associated modifications are novel signals that may be linked to the pathogenesis and development of Alzheimers disease. FundingNIH grants (R01HL122770, R01HL091905, 1P20GM130459, R01HD092431, P50HD098593, GM103440), AHA grant (17IRG33370128), Sigmund Gestetner Foundation Fellowship to P Kehoe. Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSAlzheimers disease (AD) and vascular dementia (VaD) are marked by cognitive impairment and neuropathologies caused by significant neuronal death. Associated gene mutations are rare in subjects with dementia, and the aetiology of these diseases is still not completely understood. Recent emerging evidence suggests that epigenetic changes are risk factors for the development of dementia. However, studies assessing small RNA modifications--one of the features of epigenetics--in dementia are lacking. Added value of this studyWe used high-throughput liquid chromatography-tandem mass spectrometry and small RNA sequencing to profile small RNA modifications and the composition of small RNAs in post-mortem samples of the prefrontal cortex of AD and control subjects. We detected and quantified 16 types of RNA modifications and identified distinct small non-coding RNAs and modification signatures in AD subjects compared with controls. Implications of all the available evidenceThis study identified novel types and compositions of small RNA modifications in the prefrontal cortex of AD patients compared with control subjects in post-mortem samples. The cellular locations of these RNA modifications and whether they are drivers or outcomes of AD are still not known. However, results from the present study may open new possibilities for dissecting the dementia pathology.

Source connections

Explore related subjects

cell biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhang, X., Trebak, F., Souza, L. A. C., Shi, J., Zhou, T., Kehoe, P. G., Chen, Q., Feng Earley, Y.. 2020-05-01. Evidence for unique small RNA modifications in Alzheimers disease. https://doi.org/10.1101/2020.04.30.071100

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

RCDome: A Multi-Database Human Gene Atlas of Regulated Cell Death

Introduction: Regulated cell death (RCD) governs tissue homeostasis, development, and disease, and is executed or regulated by specific genes. Yet for the researcher asking which genes execute or regulate a given RCD form, the answer is rarely simple: gene lists for the same form rarely agree across databases, many associations carry no traceable source, and most have never been systematically checked against primary literature. We built RCDome to answer the most basic question a researcher can ask: where did this gene-RCD association come from, and what is the evidence? Methods: RCDome is a multi-database human gene atlas built through a staged architecture integrating multi-source compilation, literature validation and evidence recovery, mechanistic classification, human-governed ontological adjudication, and web deployment. Five complementary evidence channels (PubMed Boolean search, curated databases, AI-assisted screening, manual curation, and Elicit systematic review) were integrated from 20 public databases into a unified matrix. Sixty-two original name strings were canonicalized into 53 RCD-related entities with curator-adjudicated operational definitions and ontological levels. Gene-RCD associations were systematically evaluated through an independent DeepSeek two-call LLM validation, Europe PMC full-text recovery and deep evidence extraction, an independent Consensus literature-search channel, and GPT-4o arbitration of disagreements. Source-grounding controls rejected extracted evidence not found verbatim in the source document, while the governance contract was enforced as executable code. Results: The compendium holds 22,473 association rows spanning 9,265 unique HGNC-validated genes (21,568 unique gene-RCD pairs). Evidence-first adjudication resolved 5,138 pairs (23.8%) as mechanistically involved; across the 4,775 role-resolved pairs, 225 (4.7%) are executors, 4,455 (93.3%) are regulators, and 95 are markers, revealing a small death-executing core embedded in a vast regulatory network. Under a separate seven-class mechanistic criterion applied to all 22,473 rows, only 3,063 (13.6%) were mechanistically confirmed and 286 (1.3%) were database-only with no verifiable paper trail. Conclusion: RCDome makes the RCD evidence landscape measurable and traceable, showing that AI-assisted curation can be verifiable, human-governed, and explicit about uncertainty. It is delivered as a Shiny web application that lets any researcher query the atlas and inspect the evidence behind each association. Availability: RCDome is freely available at https://rcdome.org/ (source code and data at https://github.com/BioCancerInformatics/RCDome).

cell biology↗
bioRxiv2026

Circadian Clock Coordination of the Notch-to-Wnt Signaling Switch Promotes Regenerative Myogenesis

Regenerative deficits of muscle stem cells (MuSCs) contribute to progressive muscle loss in muscular dystrophy. Successful regenerative repair requires a Notch to Wnt switch to allow MuSC expansion and myogenic differentiation, yet the underlying mechanisms remain poorly understood. Leveraging complementary genetic and pharmacological approaches, here we identify the circadian clock as a key regulator of the Notch to Wnt signaling transition to promote regeneration with therapeutic potential for dystrophic disease. Circadian clock activity marks cycling myogenic progenitors during muscle regeneration, and clock induction occurs in concert with Notch activation. We identify that key components of the Notch pathway are direct transcriptional targets of the clock that were induced by clock activation. Mechanistically, clock coordination of Notch and Wnt signaling promoted MuSC proliferative expansion while facilitating myogenic progression during regeneration. Importantly, this clock-regulated mechanism was preserved in dystrophin-deficient mouse and human myoblasts, and clock-activating compounds enhanced regenerative myogenesis in dystrophic muscle. Collectively, our findings uncover a circadian clock-controlled mechanism that orchestrates regenerative signaling transition with potential for therapeutic targeting to restore regenerative capacity in dystrophic disease.

cell biology↗
bioRxiv2026

The yeast Gcn2 protein kinase mediates P-body formation both through its activity with eIF2α and with non-canonical substrates

P-bodies (PBs) are control hubs for RNA processing and storage that form when translation initiation is inhibited, including during stress. In yeast, Gcn2 is the sole eIF2 alpha kinase that inhibits translation initiation in response to diverse stresses. We show that PB formation depends strongly on Gcn2 during amino acid starvation but only partially during oxidative stress. Constitutively active Gcn2 also induces PB formation in unstressed cells. Surprisingly, PBs are still constitutively formed in a gcn3 mutant strain that is insensitive to eIF2 alpha phosphorylation suggesting that Gcn2 also promotes PB formation independently of eIF2 alpha phosphorylation. Analysis of several putative Gcn2-substrates involved in RNA metabolism identified several proteins required for Gcn2-mediated PB formation. Among these, Smu2, which was not previously implicated in PB formation, localises to PBs and is required for stress-induced coalescence of mRNA granules into PBs. Together, our findings indicate that Gcn2 promotes PB formation via two complementary routes: eIF2 alpha phosphorylation, which generates untranslated mRNAs, and Smu2-dependent maturation of mRNA granules into PBs.

cell biology↗